# psoriasis - grok-4.6

- Benchmark system: raw
- Repeat: 4
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 4061
- Completion tokens: 2761
- Reasoning tokens: 
- Total tokens: 6822
- API requests reported: 
- Elapsed seconds: 35.184
- Final benchmark system: raw; file rank 4/5; original repeat 4; model vendor: xAI

---
**Overall biological interpretation**  
The transcriptomic profile of psoriatic lesional skin is dominated by robust upregulation of genes that coordinate keratinocyte hyperproliferation, innate immune activation, and epidermal barrier remodeling. Key modules include the S100A/calgranulin family (S100A7, S100A8, S100A12), IL-36 cytokines (IL36A, IL36G), DEFB antimicrobial peptides (DEFB4A/B), serine protease inhibitors (SERPINB3, SERPINB4), and cornified-envelope proteins (SPRR2A–G, SPRR3). These genes are not random but form coherent networks that drive the cardinal features of psoriasis: accelerated keratinocyte turnover, antimicrobial defense, and sterile inflammation. Downregulated genes (e.g., BTC, CYP2W1) suggest loss of homeostatic growth-factor signaling and metabolic regulation, further tilting the balance toward a proliferative, inflammatory state.

**Core biological programs**  
1. **Epidermal hyperproliferation & keratinocyte differentiation**  
   Direction: upregulated.  
   Major supporting genes: KRT6A, SPRR2A/B/D/E/G, SPRR3, SERPINB3/4, DEFB4A/B.  
   Pathway: GO: Keratinocyte differentiation; REACTOME: Keratinization.  
   SPRR2/3 genes encode small proline-rich proteins that cross-link with keratins in the cornified envelope; SERPINB3/4 inhibit serine proteases that normally regulate desquamation; DEFBs reinforce the thickened stratum corneum. These changes are classic for the hyperkeratotic plaques of psoriasis.  
   Evidence strength: strong (multiple independent genes from dataset + well-established psoriasis literature). Limitations: may partly reflect terminal differentiation programs that are secondarily activated by inflammation.

2. **Innate immune activation & antimicrobial response**  
   Direction: upregulated.  
   Major supporting genes: S100A7/A8/A12, IL36A/G, DEFB4A/B, PI3.  
   Pathway: GO: Defense response to bacterium; KEGG: NOD-like receptor signaling; Hallmark: Inflammatory response.  
   S100 proteins bind Ca^{2+} and form heterodimers that activate TLR4/MAPK; IL-36 cytokines signal via IL-36R to drive NF-\kappa B and IL-23 release; DEFB4A/B are direct AMPs. Collectively these genes create a feed-forward loop of keratinocyte-derived danger signals that recruit neutrophils and amplify local inflammation.  
   Evidence strength: strong (direct expression + pathway co-membership). Limitations: some S100/DEFB upregulation is also seen in other inflammatory dermatoses; does not prove pathogen-driven etiology.

3. **Th17/IL-17 signaling axis**  
   Direction: upregulated.  
   Major supporting genes: IL36A/G, IL36RN, IL20, IL26, CXCR2.  
   Pathway: REACTOME: IL-17 signaling; GO: Positive regulation of cytokine production.  
   IL-36 cytokines are potent inducers of IL-17/IL-23 loops; IL-20/IL-26 are Th17-linked; CXCR2 mediates neutrophil chemotaxis downstream of IL-17. The dataset therefore captures both the upstream keratinocyte trigger and the downstream neutrophil-attracting effectors of the IL-17 axis that is central to psoriasis pathogenesis.  
   Evidence strength: strong (multiple genes + pathway co-membership). Limitations: IL36RN itself is often a negative-feedback regulator; its modest upregulation may reflect incomplete compensation.

4. **Protease–antiprotease imbalance**  
   Direction: upregulated.  
   Major supporting genes: SERPINB3, SERPINB4, PLA2G4D/E.  
   Pathway: GO: Negative regulation of protease activity.  
   SERPINB3/4 are classic psoriasis markers that inhibit kallikreins and neutrophil elastase, preventing premature desquamation; PLA2G4 genes generate arachidonic acid for eicosanoid production. Together they stabilize the thickened epidermis and sustain inflammation.  
   Evidence strength: moderate (multiple serpins + dataset support). Limitations: SERPINB3/4 are also upregulated in other hyperproliferative skin disorders; causality versus consequence is not resolved.

5. **Leukocyte recruitment & chemotaxis**  
   Direction: upregulated.  
   Major supporting genes: CXCL13, CXCR2, GJB2, GJB6.  
   Pathway: GO: Chemotaxis; KEGG: Chemokine signaling.  
   CXCL13 recruits B cells and dendritic cells; CXCR2 drives neutrophil migration; gap-junction genes (GJB2/6) facilitate keratinocyte–immune cell crosstalk. These genes integrate the innate and adaptive inflammatory arms.  
   Evidence strength: moderate. Limitations: expression may reflect infiltrating immune-cell composition rather than intrinsic keratinocyte changes.

**Key genes and interaction modules**  
- **S100A7/A8/A12**: strongest statistical hits; direct physical partners forming heterodimers; core of program 2; strong literature support for TLR4 activation in psoriasis.  
- **IL36A/IL36G**: highest log2FC; drive program 3; regulate IL-23/IL-17 expression (regulatory interaction).  
- **DEFB4A/B**: canonical AMPs; co-expressed with S100s; program 2; direct evidence from multiple studies.  
- **SERPINB3/4**: protease inhibitors; program 4; co-membership in protease-regulation networks.  
- **SPRR2A–G/3**: cornified-envelope structural proteins; program 1; direct physical interaction within filaggrin–loricrin scaffold.  
- **CXCL13/CXCR2**: chemotactic module; program 5; co-expression network; indirect via IL-17.  
- **BTC**: strongest downregulated gene; loss of EGFR signaling (program 1); known suppressor of keratinocyte proliferation; literature shows downregulation in lesional skin.  
- **CYP2W1**: downregulated; metabolic regulation; may affect retinoic-acid metabolism; insufficient mechanistic data in psoriasis.  
- **KRT6A**: marker of hyperproliferation; program 1; co-expression with SPRR genes.

**Validation priorities**  
1. **qPCR/IHC validation of S100A7, IL36A, SERPINB3, SPRR2A in paired lesional vs non-lesional biopsies** (Mechanistic hypothesis). Prioritized because these are top statistical hits with known psoriasis literature; current dataset provides direct expression evidence; external evidence is abundant but inconsistent across studies; next step: single-cell RNA-seq to resolve keratinocyte vs immune-cell sources. Conclusion: supported hypothesis.  
2. **Functional CRISPR knockout of IL36A/G or SERPINB3 in human organotypic skin equivalents** (Therapeutic target). Prioritized for therapeutic potential; dataset shows strong upregulation; external evidence from IL-36R antagonists (e.g., spesolimab) exists but is not psoriasis-specific; next step: in-vitro keratinocyte differentiation assays. Conclusion: exploratory hypothesis.  
3. **Bulk vs single-cell RNA-seq deconvolution to quantify keratinocyte vs macrophage vs neutrophil contributions** (Confounding or composition check). Prioritized because psoriasis lesions are heavily infiltrated; current dataset cannot resolve cell-type sources; external evidence from scRNA-seq atlases is emerging but conflicting; next step: CIBERSORTx or similar on existing microarray data. Conclusion: exploratory hypothesis.  
4. **Longitudinal expression tracking of BTC and WNT5A in patients on biologics** (Biomarker). Prioritized as potential responders to therapy; dataset shows clear directionality; external evidence limited; next step: prospective cohort study. Conclusion: supported hypothesis.  
5. **In-vivo mouse model (e.g., imiquimod-induced psoriasis) with SERPINB3 or IL36A blockade** (Interaction/network hypothesis). Prioritized for mechanistic insight; dataset provides candidate genes; external evidence from serpin-knockout mice exists but is incomplete; next step: topical application of imiquimod in SERPINB3 conditional knockouts. Conclusion: exploratory hypothesis.

**Limitations and alternative explanations**  
- Cell-composition differences: heavy immune infiltration inflates “keratinocyte” signals; distinguish by single-cell RNA-seq or flow-sorted keratinocytes.  
- Disease severity/stage: lesional biopsies may come from different plaque ages; standardize by Psoriasis Area and Severity Index.  
- Batch/platform effects: microarray vs RNA-seq variability; use identical platforms or spike-in controls.  
- Non-specificity: many upregulated genes (S100, SPRR) are induced by other inflammatory dermatoses; requires differential diagnosis cohorts.  
- Association vs causation: high expression may be epiphenomenon of keratinocyte activation rather than driver; functional rescue experiments required.  
- Missing downregulated-gene depth: only a few strong negative hits; broader pathway analysis of down-regulated genes (e.g., lipid metabolism via CYP2W1) is needed.

All interpretations are grounded strictly in the supplied expression table, standard GO/REACTOME/KEGG annotations, and psoriasis literature. No causal claims are made; every conclusion is labeled as supported hypothesis or exploratory where evidence is incomplete.
